Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States
Study of Ribociclib and Everolimus in HGG and DIPG
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05843253
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05768139
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇮🇹Fondazione Policlinico Universitario A Gemelli-Rome, Roma, Lazio, Italy
🇮🇹Istituto Europeo di Oncologia, Milano, Lombardia, Italy
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05766410
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
🇨🇳Department of Oncology,National Taiwan University Hospital, Taipei, Taiwan
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 162
- Registration Number
- NCT05625087
- Locations
- 🇫🇷
Clinique de l'Europe Amiens - CTHE, Amiens, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre Hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, France
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT05573555
- Locations
- 🇺🇸
Moffitt McKinley Hospital, Tampa, Florida, United States
🇺🇸Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT05569187
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.